Keytruda
Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal
Trodelvy, Triple Negative Breast Neoplasms, Metastatic to, Keytruda, Overall Survival
Merck’s Injectable Keytruda Shows Promising Results in Pivotal Trial
Keytruda, subcutaneous injection, intravenous formula, non-small cell lung cancer, pivotal trial, Merck
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
Keytruda and Lenvima Combination Shows Mixed Results in Gastroesophageal Cancer Trial
Keytruda, Lenvima, gastroesophageal cancer, clinical trial, survival endpoints, progression-free survival, overall survival
Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda
Merck Discontinues TIGIT and LAG-3 Programs Amid Efficacy Concerns
Merck, TIGIT, LAG-3, Keytruda, Cancer Therapy, Clinical Trials
Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial
Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival
Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq
Merck’s Subcutaneous Keytruda Shows Non-Inferiority in Phase 3 Trial, Paving Way for Regulatory Discussions
Merck, Keytruda, subcutaneous, cancer immunotherapy, phase 3 trial, non-inferiority, regulatory submissions